In a major move, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is acquiring most of 23andMe’s assets for $256 million, including its personal genome service, research services, biobank, and ...

Officials for retailer Claire's filed for bankruptcy protection on Wednesday as its operating costs rise while demand for its ...

A federal judge has given the green light for the sale of genetics and biotech company 23andMe.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Regeneron Pharmaceuticals, Inc.

Regeneron is having difficulties again with a contract manufacturer, reporting the delay of two FDA regulatory decisions due this month for Eylea.

Nordstrom is set to close two locations in California and Missouri. See where they are and when they'll shutter.

REGENERON PHARMACEUTICALS (REGN): Free Stock Analysis Report This article Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines originally appeared on Benzinga.com ...

(RTTNews) - Regeneron Pharmaceuticals (REGN) announced earnings for second quarter that beat the Street estimates. The company's bottom line totaled $1.392 billion, or $12.81 per share. This ...

Regeneron (NASDAQ:REGN), a leading biotechnology firm known for its work in immunology and ophthalmology, reported Q2 2025 earnings on August 1, 2025.

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Friday reported second-quarter earnings of $1.39 billion.